期刊文献+

血清胱抑素C与尿白蛋白排泄率联合检测对原发性高血压患者早期肾损害的诊断价值 被引量:15

Diagnostic Value of Serum Cystatin C and UAER for Early Renal Function Injury in Patients with Essential Hypertension
暂未订购
导出
摘要 目的:探讨血清胱抑素C(CysC)和尿白蛋白排泄率(UAER)联合检测,对高血压患者早期肾损害的诊断价值。方法:测定320例确诊原发性高血压患者内生肌酐清除率(Ccr)并据此分为肾小球功能正常组(A组,Ccr≥80ml/min)和肾小球功能损害组(B组,Ccr<80ml/min)。再测定A组、B组及正常对照组血清CysC浓度UAER和血清肌酐(Scr)水平,分析以上指标单检和联检对早期肾损害阳性检出率差异。结果:A组、B组CysC、UAER和Scr水平均显著高于对照组(P<0.05)。B组高于A组(P<0.01)。A组患者血清CysC、UAER单检阳性率分别为41.84%和36.73%,二者联合检测的阳性率增至58.16%(P<0.01),B组患者血清CysC、UAER单检阳性率分别为90.54%和80.18%,二者联检的阳性率增至97.75%(P<0.01)。结论:血清Cy-sC、UAER联合检测有助于及早发现原发性高血压早期肾损害。 Objective:To investigate serum cystatin C(CysC) and UAER in patients with essential hypertension,and evaluate diagnostic value for early renal function injury in hypertension. Method:According to creatinine clearance (Ccr),320 patients with newly diagnosed hypertension were divided into two groups:normal renal function group (A group,Ccr≥80 ml/min) and impaired renal function group(B group,Ccr<80 ml/min).Serum CysC,UAER and serum creatinine (Scr) were measured in 320 patients and 120 healthy persons.Results:SysC,UAER and Scr in A group and B group were higher than control group(P<0.05),while serum CysC,UAER and Scr in A group were significantly lower than B group(P<0.01). In A group,positive rate of serum CysC was 41.84%;positive rate of UAER was 36.73%;positive rate of cystatin C+UAER was 58.16%(P<0.01). In B group,positive rate of serum CysC was 90.54%;positive rate of UAER was 80.18%;positive rate of CysC+UAER was 97.75%.Conclusion:Combinative measurement of serum cystatin C and UAER is helpful for diagnosis of early renal function injury in patients with essential hypertension.
出处 《微循环学杂志》 2011年第1期39-41,I0002,共4页 Chinese Journal of Microcirculation
关键词 原发性高血压 胱抑素C 尿白蛋白排泄率 早期肾损害 Essential hypertension Cystatin C UAER Early renal function ingury
  • 相关文献

参考文献9

  • 1Hohenstein K,Watschinger B.Hypertension and the kidney.Wien Med Wochenschr,2008,158 (13-14):359-364.
  • 2李梦,胡健,方慧娟,樊新,李佳宇.高血压合并糖耐量减低患者血清瘦素水平与尿微量白蛋白的相关性[J].中国动脉硬化杂志,2005,13(5):613-618. 被引量:3
  • 3Taglieri N,Koenig W,Kaski JC.Cystatin C and cardiovascular risk.Clin Chem,2009,55 (11):1 932-1 943.
  • 4Chaudhary K,Phadke G,Nistala R,et al.The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease.Curr Diab Rep,2010,10(1):37-42.
  • 5Prats M,Font R,Bardaj A,et al.Cystatin C and cardiac hypertrophy in primary hypertension.Blood Press,2010,19(1):20-25.
  • 6McMurray MD,Trivax JE,McCullough PA.Serum cystatin C,renal filtration function,and left ventricular remodeling.Circ Heart Fail,2009,2(2):86-89.
  • 7Palatini P,Benetti E,Zanier A,et al.Cystatin C as predictor of microalbuminuria in the early stage of hypertension.Nephron Clin Pract,2009,113(4):c309-c314.
  • 8Wu AY,Low LP.Managing vascular risk in hypertension with a focus on microalbuminuria:attitude and practices.Singapore Med J,2009,50(10):976-981.
  • 9Zoccali C.Endothelial dysfunction and the kidney:emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension.J Am Soc Nephrol,2006,17(4 Suppl 2):61-63.

二级参考文献2

共引文献2

同被引文献107

引证文献15

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部